AstraZeneca’s MedImmune In-Licenses Pfizer’s Tremelimumab
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 10 (Table of Contents)
Published: 31 Oct-2011
DOI: 10.3833/pdr.v2011.i10.1589 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Pfizer has out-licensed tremelimumab, a fully human CTLA-4 (cytotoxic T-lymphocyte antigen 4) monoclonal antibody that previously demonstrated unimpressive efficacy in a Phase III trial for advanced melanoma, to AstraZeneca’s MedImmune, which plans to explore the drug for a number of potential cancer indications...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS